title: Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma.
authors.forename: M A
authors.initials: MA
authors.lastname: Weiner
authors.forename: M B
authors.initials: MB
authors.lastname: Harris
authors.forename: M
authors.initials: M
authors.lastname: Lewis
authors.forename: R
authors.initials: R
authors.lastname: Jones
authors.forename: H
authors.initials: H
authors.lastname: Sherry
authors.forename: E J
authors.initials: EJ
authors.lastname: Feurer
authors.forename: J
authors.initials: J
authors.lastname: Johnson
authors.forename: E
authors.initials: E
authors.lastname: Lahman
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005121:Extremities; D005500:Follow-Up Studies; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery
chemical_list: D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate